{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Temporal Clonal Replacement from Protective TRM to Pathogenic Effector Clones",
"mechanism": "CD8+ T cells shift from neuroprotective tissue-resident memory (CD69+CD103+) to cytotoxic terminally-differentiated effectors (KLRG1+PD-1-) via CXCR3-mediated recruitment during neurodegeneration progression.",
"target_gene": "CXCR3",
"confidence_score": 0.7,
"novelty_score": 0.6,
"feasibility_score": 0.5,
"impact_score": 0.8,
"composite_score": 0.68,
"testable_prediction": "CXCR3 blockade in aged 5xFAD mice will preserve TRM cells while blocking pathogenic effector infiltration, reducing neuron loss without impairing viral surveillance.",
"skeptic_concern": "Mechanistic driver of TRM-to-effector transition remains undefined; circularity risk if aging causes replacement and replacement causes pathology."
},
{
"rank": 2,
"title": "Chronic Antigen Exposure Driving Terminal Differentiation",
"mechanism": "Accumulation of misfolded proteins (Aβ/α-synuclein) or latent viral antigens drives persistent CD8+ T cell stimulation through MHC-I presentation, resulting in progressive terminal differentiation and loss of protective function.",
"target_gene": "MHC-I (B2M)",
"confidence_score": 0.55,
"novelty_score": 0.65,
"feasibility_score": 0.45,
"impact_score": 0.7,
"composite_score": 0.60,
"testable_prediction": "Single-cell TCR sequencing of CD8+ T cells from aged brains will show antigen-expanded clones with exhausted/effector phenotypes that correlate with local antigen burden.",
"skeptic_concern": "Specific antigenic triggers remain unidentified; distinguishing pathogenic from bystander activation is technically challenging."
},
{
"rank": 3,
"title": "Microenvironmental IL-15/IL-12 Dysregulation Favoring Effector Commitment",
"mechanism": "Aging brain microenvironment exhibits elevated IL-15 and IL-12 levels that drive CD8+ T cell differentiation toward KLRG1+ effectors while undermining TRM maintenance, creating a niche shift favoring cytotoxicity.",
"target_gene": "IL15",
"confidence_score": 0.5,
"novelty_score": 0.55,
"feasibility_score": 0.5,
"impact_score": 0.65,
"composite_score": 0.55,
"testable_prediction": "Conditional IL-15 deletion in brain endothelial cells or blockade with IL-15R-Fc in aged mice will maintain CD69+CD103+ TRM populations and reduce cytotoxic CD8+ infiltrates.",
"skeptic_concern": "Cytokine redundancy and systemic effects of IL-15 inhibition may limit specificity; optimal temporal window for intervention unclear."
}
],
"consensus_points": [
"CD8+ T cells serve both protective (immune surveillance) and pathogenic (cytotoxic) roles in neurodegeneration depending on activation state",
"CXCR3-mediated recruitment pathway represents the most actionable therapeutic target for selective modulation",
"A 'one cell type, two functions' model better explains contradictory literature than absolute protection or harm"
],
"dissent_points": [
"Whether targeting infiltration (Hypothesis 1) or modulating existing cells (Hypotheses 2/3) is the superior therapeutic strategy remains unresolved",
"The relative contribution of brain-resident versus recruited CD8+ T cells to net outcomes is contested"
],
"debate_summary": "The debate converged on a temporal-differentiation model where CD8+ TRM cells provide beneficial immune surveillance but are progressively replaced by recruited KLRG1+ effectors via CXCR3-mediated chemotaxis, reconciling protective and harmful roles. The strongest hypothesis (Hypothesis 1) offers a translationally actionable framework—immune normalization via CXCR3 blockade—though the Skeptic correctly identified that the mechanistic trigger for TRM-to-effector transition remains the critical missing link requiring resolution before rational therapy design."
}